NO971704L - Fremgangsmåte for reversering av multimedikamantsesistens - Google Patents
Fremgangsmåte for reversering av multimedikamantsesistensInfo
- Publication number
- NO971704L NO971704L NO971704A NO971704A NO971704L NO 971704 L NO971704 L NO 971704L NO 971704 A NO971704 A NO 971704A NO 971704 A NO971704 A NO 971704A NO 971704 L NO971704 L NO 971704L
- Authority
- NO
- Norway
- Prior art keywords
- reversing
- resistance
- multimedia
- procedure
- dihydronaphthalene
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 3
- FCEHBMOGCRZNNI-UHFFFAOYSA-N 1-benzothiophene Chemical compound C1=CC=C2SC=CC2=C1 FCEHBMOGCRZNNI-UHFFFAOYSA-N 0.000 abstract 4
- UFWIBTONFRDIAS-UHFFFAOYSA-N Naphthalene Chemical compound C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 abstract 4
- 241000124008 Mammalia Species 0.000 abstract 3
- KEIFWROAQVVDBN-UHFFFAOYSA-N 1,2-dihydronaphthalene Chemical compound C1=CC=C2C=CCCC2=C1 KEIFWROAQVVDBN-UHFFFAOYSA-N 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 2
- RFRXIWQYSOIBDI-UHFFFAOYSA-N benzarone Chemical compound CCC=1OC2=CC=CC=C2C=1C(=O)C1=CC=C(O)C=C1 RFRXIWQYSOIBDI-UHFFFAOYSA-N 0.000 abstract 2
- SIKJAQJRHWYJAI-UHFFFAOYSA-N benzopyrrole Natural products C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 abstract 2
- 208000035269 cancer or benign tumor Diseases 0.000 abstract 2
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 abstract 2
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 abstract 2
- 150000002475 indoles Chemical class 0.000 abstract 2
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 230000000174 oncolytic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Emergency Medicine (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Furan Compounds (AREA)
- Indole Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US32317694A | 1994-10-14 | 1994-10-14 | |
| PCT/US1995/013036 WO1996011677A1 (en) | 1994-10-14 | 1995-10-13 | Methods for treating resistant tumors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NO971704D0 NO971704D0 (no) | 1997-04-14 |
| NO971704L true NO971704L (no) | 1997-05-13 |
Family
ID=23258042
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO971704A NO971704L (no) | 1994-10-14 | 1997-04-14 | Fremgangsmåte for reversering av multimedikamantsesistens |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US6121292A (de) |
| EP (2) | EP0820769A3 (de) |
| JP (1) | JPH10512544A (de) |
| CN (1) | CN1168631A (de) |
| AU (1) | AU702301B2 (de) |
| CA (1) | CA2202661A1 (de) |
| CZ (1) | CZ113797A3 (de) |
| FI (1) | FI971568A7 (de) |
| HU (1) | HUT77604A (de) |
| IL (1) | IL115582A0 (de) |
| MX (1) | MX9702700A (de) |
| NO (1) | NO971704L (de) |
| WO (1) | WO1996011677A1 (de) |
| ZA (1) | ZA958688B (de) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ZA961564B (en) * | 1995-02-28 | 1997-08-27 | Lilly Co Eli | Methods of inhibiting ovarian cancer. |
| JPH08253417A (ja) * | 1995-02-28 | 1996-10-01 | Eli Lilly & Co | 脳又はｃｎｓのエストロゲン陽性腫瘍抑制用製剤 |
| AU7602896A (en) * | 1995-11-07 | 1997-05-29 | Eli Lilly And Company | Methods for treating resistant tumors |
| CA2206752A1 (en) * | 1996-07-02 | 1998-01-02 | George Joseph Cullinan | Benzothiophene compounds, intermediates, processes, and methods of use |
| CA2214922A1 (en) * | 1996-09-27 | 1998-03-27 | Eli Lilly And Company | Benzothiophene compounds, compositions, and methods |
| AU741439B2 (en) | 1996-12-30 | 2001-11-29 | Battelle Memorial Institute | Formulation and method for treating neoplasms by inhalation |
| EP0973517A4 (de) | 1997-04-30 | 2002-07-24 | Lilly Co Eli | Antithrombotische mittel |
| EP0980366B1 (de) | 1997-04-30 | 2004-06-09 | Eli Lilly And Company | Antithrombosemittel |
| EP0980367A4 (de) | 1997-04-30 | 2003-03-19 | Lilly Co Eli | Antithrombosemittel |
| CA2288224A1 (en) | 1997-04-30 | 1998-11-05 | Mary George Johnson | Antithrombotic agents |
| US5840721A (en) * | 1997-07-09 | 1998-11-24 | Ontogen Corporation | Imidazole derivatives as MDR modulators |
| US6284756B1 (en) | 1998-04-30 | 2001-09-04 | Eli Lilly And Company | Antithrombotic agents |
| WO2000019991A1 (en) * | 1998-10-02 | 2000-04-13 | Battelle Memorial Institute | Inhalation chemotherapy for prevention and treatment of metastatic tumors in the lung |
| PT997460E (pt) * | 1998-10-28 | 2003-03-31 | Lilly Co Eli | Compostos benzotiofenos como agentes antitromboticos e seus intermediarios |
| AU2998900A (en) * | 1999-02-19 | 2000-09-04 | Leslee S. Brooks | Zinc chloride in treating skin diseases |
| WO2002020478A1 (en) * | 2000-08-24 | 2002-03-14 | Dublin City University | N-benzylindole-3-acetic acid derivatives for use in the treatment of drug resistan cancer |
| US6693099B2 (en) | 2000-10-17 | 2004-02-17 | The Procter & Gamble Company | Substituted piperazine compounds optionally containing a quinolyl moiety for treating multidrug resistance |
| US6376514B1 (en) | 2000-10-17 | 2002-04-23 | The Procter & Gamble Co. | Substituted six-membered heterocyclic compounds useful for treating multidrug resistance and compositions and methods thereof |
| US7425565B2 (en) * | 2002-05-09 | 2008-09-16 | Cedars-Sinai Medical Center | Use of benzothiopenes to treat and prevent prostate cancer |
| US6630454B2 (en) * | 2001-09-10 | 2003-10-07 | Ramot At Tel-Aviv University Ltd. | Method and pharmaceutical composition for the treatment of cancer |
| WO2004010937A2 (en) * | 2002-07-26 | 2004-02-05 | Advanced Research & Technology Institute At Indiana University | Method of treating cancer |
| CN1281210C (zh) * | 2003-11-29 | 2006-10-25 | 胡汛 | 五味子乙素在制备治疗肿瘤药物中的应用 |
| US7772271B2 (en) * | 2004-07-14 | 2010-08-10 | Ptc Therapeutics, Inc. | Methods for treating hepatitis C |
| WO2006019831A1 (en) * | 2004-07-14 | 2006-02-23 | Ptc Therapeutics, Inc. | Methods for treating hepatitis c |
| US7781478B2 (en) * | 2004-07-14 | 2010-08-24 | Ptc Therapeutics, Inc. | Methods for treating hepatitis C |
| US7868037B2 (en) * | 2004-07-14 | 2011-01-11 | Ptc Therapeutics, Inc. | Methods for treating hepatitis C |
| WO2006019832A1 (en) * | 2004-07-22 | 2006-02-23 | Ptc Therapeutics, Inc. | Thienopyridines for treating hepatitis c |
| FR2873692B1 (fr) * | 2004-07-29 | 2006-12-01 | Univ Claude Bernard Lyon | COMPOSITIONS CONTENANT, EN ASSOCIATION AVEC UN AGENT ANTIMICROBIEN, UN COMPOSE THIOPHENIQUE OU BENZOTHIOPHENIQUE DE FORMULE(I)PRESENTANT UNE ACTIVITE INHIBITRICE DE POMPE NorA |
| FR2913017A1 (fr) * | 2007-02-23 | 2008-08-29 | Cerep Sa | Derives de piperidine et piperazine comme agents anti-neoplasiques ou inhibiteurs de proliferation cellulaire |
| WO2016097071A1 (en) * | 2014-12-18 | 2016-06-23 | F. Hoffmann-La Roche Ag | Estrogen receptor modulators and uses thereof |
| TWI874834B (zh) * | 2014-12-18 | 2025-03-01 | 瑞士商赫孚孟拉羅股份公司 | 四氫-吡啶并[3,4-b]吲哚雌激素受體調節劑及其用途 |
| CN108129375B (zh) * | 2018-01-30 | 2020-04-28 | 中山大学 | 化合物及其制备方法与在制备肿瘤耐药逆转剂中的应用 |
| CN117603219B (zh) * | 2023-11-29 | 2025-08-08 | 浙江大学 | 一种p-糖蛋白抑制剂及其制备方法和应用 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4230862A (en) * | 1975-10-28 | 1980-10-28 | Eli Lilly And Company | Antifertility compounds |
| US4133814A (en) | 1975-10-28 | 1979-01-09 | Eli Lilly And Company | 2-Phenyl-3-aroylbenzothiophenes useful as antifertility agents |
| US4380635A (en) | 1981-04-03 | 1983-04-19 | Eli Lilly And Company | Synthesis of acylated benzothiophenes |
| US4418068A (en) | 1981-04-03 | 1983-11-29 | Eli Lilly And Company | Antiestrogenic and antiandrugenic benzothiophenes |
| US5023252A (en) | 1985-12-04 | 1991-06-11 | Conrex Pharmaceutical Corporation | Transdermal and trans-membrane delivery of drugs |
| US5011472A (en) | 1988-09-06 | 1991-04-30 | Brown University Research Foundation | Implantable delivery system for biological factors |
| US5482949A (en) * | 1993-03-19 | 1996-01-09 | Eli Lilly And Company | Sulfonate derivatives of 3-aroylbenzo[b]thiophenes |
| ZA948025B (en) * | 1993-10-15 | 1996-04-15 | Lilly Co Eli | Methods for treating resistant neoplasms |
| WO1995017382A1 (en) * | 1993-12-21 | 1995-06-29 | Eli Lilly And Company | Non-peptide tachykinin receptor antagonists |
| JPH09507071A (ja) * | 1993-12-21 | 1997-07-15 | イーライ・リリー・アンド・カンパニー | アミロイド原性ペプチドに関連した状態を治療又は予防する方法 |
| US5492927A (en) * | 1993-12-21 | 1996-02-20 | Eli Lilly And Company | Non-peptide tachykinin receptor antagonists to treat allergy |
-
1995
- 1995-10-12 IL IL11558295A patent/IL115582A0/xx unknown
- 1995-10-13 EP EP97203340A patent/EP0820769A3/de not_active Withdrawn
- 1995-10-13 AU AU38298/95A patent/AU702301B2/en not_active Ceased
- 1995-10-13 HU HU9702309A patent/HUT77604A/hu unknown
- 1995-10-13 CA CA002202661A patent/CA2202661A1/en not_active Abandoned
- 1995-10-13 JP JP8513362A patent/JPH10512544A/ja active Pending
- 1995-10-13 MX MX9702700A patent/MX9702700A/es unknown
- 1995-10-13 EP EP95307298A patent/EP0709090A3/de not_active Ceased
- 1995-10-13 CN CN95196608A patent/CN1168631A/zh active Pending
- 1995-10-13 CZ CZ971137A patent/CZ113797A3/cs unknown
- 1995-10-13 WO PCT/US1995/013036 patent/WO1996011677A1/en not_active Ceased
- 1995-10-13 ZA ZA958688A patent/ZA958688B/xx unknown
- 1995-10-13 FI FI971568A patent/FI971568A7/fi unknown
-
1996
- 1996-06-28 US US08/672,834 patent/US6121292A/en not_active Expired - Fee Related
- 1996-06-28 US US08/674,771 patent/US6124311A/en not_active Expired - Fee Related
-
1997
- 1997-04-14 NO NO971704A patent/NO971704L/no unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO1996011677A1 (en) | 1996-04-25 |
| CN1168631A (zh) | 1997-12-24 |
| FI971568A0 (fi) | 1997-04-14 |
| IL115582A0 (en) | 1996-01-19 |
| ZA958688B (en) | 1997-04-14 |
| HUT77604A (hu) | 1998-06-29 |
| AU702301B2 (en) | 1999-02-18 |
| AU3829895A (en) | 1996-05-06 |
| FI971568L (fi) | 1997-06-12 |
| JPH10512544A (ja) | 1998-12-02 |
| NO971704D0 (no) | 1997-04-14 |
| CA2202661A1 (en) | 1996-04-25 |
| MX9702700A (es) | 1997-06-28 |
| EP0820769A3 (de) | 1998-08-19 |
| EP0820769A2 (de) | 1998-01-28 |
| US6124311A (en) | 2000-09-26 |
| US6121292A (en) | 2000-09-19 |
| CZ113797A3 (en) | 1997-09-17 |
| EP0709090A2 (de) | 1996-05-01 |
| FI971568A7 (fi) | 1997-06-12 |
| EP0709090A3 (de) | 1996-08-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO971704L (no) | Fremgangsmåte for reversering av multimedikamantsesistens | |
| AR007609A1 (es) | Una composicion farmaceutica | |
| Erl et al. | Monocytic cell adhesion to endothelial cells stimulated by oxidized low density lipoprotein is mediated by distinct endothelial ligands | |
| ES2176600T3 (es) | Derivado de la propiofenona y procedimientos para su preparacion. | |
| ES2133714T3 (es) | Compuestos heterociclicos para el tratamiento de trastornos del snc y cardiovasculares. | |
| MX9304359A (es) | Derivados de rapamicina. | |
| ES2154789T3 (es) | Procedimiento para la fabricacion de xileno. | |
| MX9304360A (es) | Derivados de rapamicina y composiciones farmaceuticas de los mismos. | |
| AU9536898A (en) | 4-heteroaryl-tetrahydroquinolines and their use as inhibitors of the holesterin-ester transfer protein | |
| ES540645A0 (es) | Aparato para el tratamiento del plasma. | |
| Agnew et al. | Isoflurane and coronary heart disease | |
| DE69131667D1 (de) | Proteinkinase-c-modulatoren mit entzündungshemmender und antiviraler aktivität | |
| CO5160295A1 (es) | Nuevas combinaciones farmaceuticas para inhibidores de la nos cionalmente un ssri | |
| EA199800867A1 (ru) | Соединения тетрагидробетакарболина | |
| ES2120962T3 (es) | Composicion antivirica. | |
| EA199800152A1 (ru) | Лечение синдрома дефицита внимания/гиперактивности | |
| DK0426785T3 (da) | Præparater og fremgangsmåder til behandling af virale infektioner | |
| DK341583D0 (da) | Fremgangsmade til isomerisation af styrenoxid eller homologe til betaphenylaldehyder | |
| DE69327113D1 (de) | Methode zum erzeugen von analgie mittels neurotrophine | |
| DE59105500D1 (de) | Phenylsulfonamid-substituierte Pyridinalken- und -aminooxyalkancarbonsäure-derivate. | |
| ZA912932B (en) | Method and composition for treating psoriasis | |
| KR910009271A (ko) | 15-케토-프로스타글란딘 화합물을 이용한 폐 부전증의 치료 | |
| Kawara et al. | Disseminated superficial actinic porokeratosis in a patient undergoing treatment with long‐term narrowband ultraviolet B for psoriasis | |
| Harada et al. | Changes in energy during treatment of depression: an analysis of duloxetine in double‐blind placebo‐controlled trials | |
| Charbonneau et al. | VIIth International Congress of Virology |